SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Cell signaling and cell communication === Neither sponges nor the placozoan Trichoplax adhaerens appear to be equipped with neuron synapses, however they both possess several factors related to the same synaptic function. Therefore, it is likely that central features involved in synaptic transmission arose early in metazoan evolution, most likely around the time that much of the life on Earth was transitioning to multicellularity. It was found that the Munc18/syntaxin 1 complex could be an important component for the production of the SNARE protein. The secretion of SNARE protein from synaptic vesicles is believed to be critical for neuronal communication. The Munc18/syntaxin 1 complex found in M. brevicollis is both structurally and functionally similar to the metazoan complex. This suggests that it constitutes an important step in the reaction pathway toward SNARE assembly. It is believed that the common ancestor of choanoflagellates and metazoans used this primordial secretion machinery as a precursor to synaptic communication. This mechanism would eventually be used for cell-cell communication in animals.
== Wallerian Degeneration == Main article: Wallerian degeneration Wallerian degeneration is a process that occurs after axonal injury. This is specifically in cases of axonotmesis and neurotmesis. It represents an innate immune response within the peripheral nervous system which is essential for preparation of regeneration. After the injury, the distal portion of the axon undergoes fragmentation, typically beginning within the first 1-2 days, this is then followed by disintegration of an axon and its myelin sheath. Schwann cells and macrophages play essential roles in this process by clearing axonal and myelin debris through phagocytosis; this is a process that occurs within 7 days and is completed within two weeks. This immune mediated response is essential for regeneration because myelin contains molecules that inhibit axonal regeneration. Schwann cells also contribute by releasing cytokines and chemokines that recruit macrophages and promote a regenerative environment. This is a process that allows regenerating axons to grow along pathways that are formed by Schwann cells. Efficient Wallerian degeneration is necessary for functional recovery, impaired or delayed immune responses can ultimately result in reduced regeneration and poorer clinical outcomes.
== Structure == Creatinase is a homodimeric enzyme with a calculated molecular mass of approximately 94,000 ± 2,000 Da. Each monomer subunit contains 403 amino-acid residues split between two distinct structural domains. The enzyme was purified and crystallized in 1976 after being extracted from P. putida.
Sources: en.wikipedia.org
=== Research conducted === In 1963, Nikolai Kardashev and Gennady Borissovich Sholomitskii studied the CTA 102 radio source on the 920 MHz band from the Crimea Deep Space Station, looking for signs of a Type III civilization. CTA 102 had been discovered by Sholomitskii a year earlier, and Kardashev quickly saw it as a possible artificial source to study in order to validate his classification. The observation lasted until February 1965, and on April 12, Sholomitskii announced to the press (via the Russian ITAR-TASS) that Soviet astronomers had discovered a signal that could be of extraterrestrial origin. On April 14, he gave a conference in Moscow where he repeated his announcement; but by November 1964, two American astronomers had identified CTA 102 as a quasar, and their publication definitively closed the "CTA 102 case". It was the study of this source that had led to the Byurakan conference in 1964. In 1975 and 1976, the American astronomers Frank Drake and Carl Sagan searched at Arecibo for signs of Type II civilizations in four galaxies of the Local Group: M33, M49, Leo I and Leo II. The year before, the two men had sent mankind's first message to M13. The results were published as "The Search for Extraterrestrial Intelligence" in Scientific American in May 1975. In 1976, Kardashev, Troitskii, and Gindilis used the RATAN-600 radio telescope in the North Caucasus to search for signals from Type II or III civilizations in the Milky Way and other nearby galaxies.
The aqueous humour is a transparent water-like fluid similar to blood plasma, but containing low protein concentrations. It is secreted from the ciliary body, a structure supporting the lens of the eyeball. It fills both the anterior and the posterior chambers of the eye, and is not to be confused with the vitreous humour, which is located in the space between the lens and the retina, also known as the posterior cavity or vitreous chamber. Blood cannot normally enter the eyeball.
== Analytical methods == The "acrolein test" is for the presence of glycerin or fats. A sample is heated with potassium bisulfate, and acrolein is released if the test is positive. When a fat is heated strongly in the presence of a dehydrating agent such as potassium bisulfate (KHSO4), the glycerol portion of the molecule is dehydrated to form the unsaturated aldehyde, acrolein (CH2=CH–CHO), which has the odor peculiar to burnt cooking grease. More modern methods exist. In the US, EPA methods 603 and 624.1 are designed to measure acrolein in industrial and municipal wastewater streams.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.